Indeed, inhibition of the EMT activator ZEB1 by the HDAC inhibitor mocetinostat has been shown to impede drug resistance to oncotherapy in lung and pancreatic cancer.504, 505. This evidence concerns the gene ZEB1 and pancreatic neoplasm.